Publications du laboratoire
Adjusting D-dimer to lung disease extent to exclude Pulmonary Embolism in COVID-19 patients (Co-LEAD) - Archive ouverte HAL
Article Dans Une Revue Thrombosis and Haemostasis Année : 2022

Adjusting D-dimer to lung disease extent to exclude Pulmonary Embolism in COVID-19 patients (Co-LEAD)

1 IThEM - U1140 - Innovations thérapeutiques en hémostase = Innovative Therapies in Haemostasis
2 FAC - CMI - Fondation Alain Carpentier - (Centre Médical International) [Paris]
3 AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
4 Innovte - F-Crin INvestigation Network On Venous Thrombo-Embolism [CHU Saint-Etienne]
5 PhysMed Paris - Physique pour la médecine
6 Centre hospitalier Saint-Joseph [Paris]
7 CHIMERE - CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516
8 CHU Amiens-Picardie
9 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
10 TIMC - Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525
11 CHRU Brest - Centre Hospitalier Régional Universitaire de Brest
12 GETBO - Groupe d'Etude de la Thrombose de Bretagne Occidentale
13 CIC Brest - Clinique d'Investigation Clinique
14 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
15 PCVP / CARDIO - Marqueurs pronostiques et facteurs de régulations des pathologies cardiaques et vasculaires - UFC ( UR 3920)
16 CRESS (U1153 / UMR_A 1125) - Centre for Research in Epidemiology and Statistics | Centre de Recherche Épidémiologie et Statistiques
17 UPD5 - Université Paris Descartes - Paris 5
18 PARCC (UMR_S 970/ U970) - Paris-Centre de Recherche Cardiovasculaire
19 UGA - Université Grenoble Alpes
20 CIC 1418 - CIC - HEGP
Gilles Chatellier
  • Fonction : Auteur

Résumé

Introduction: D-dimer measurement is a safe tool to exclude pulmonary embolism (PE) but its specificity decreases in COVID-19. Our aim was to derive a new algorithm with specific D-dimer threshold in COVID-19 patients. Methods: We conducted a French multicenter, retrospective cohort study among 774 COVID-19 patients with suspected PE. D-dimer threshold adjusted to computed tomography (CT) extent of lung damage was derived in a patient set (n=337), and its safety assessed in an independent validation set (n=337). Results: According to ROC curves, in the derivation set D-dimer safely excluded PE, with one false negative when using a 900 ng/mL threshold when lung damage extent was <50% and 1700 ng/mL when lung damage extent was ≥50%. In the derivation set, the algorithm sensitivity was 98.2% (95% CI: 94.7–100.0) and its specificity 28.4% (95% CI: 24.1–32.3). The negative likelihood ratio (NLR) was 0.06 (95% CI: 0.01–0.44) and the area under the curve (AUC) was 0.63 (95% CI: 0.60–0.67). In the validation set, sensitivity and specificity were 96.7% (95% CI: 88.7–99.6) and 39.2% (95% CI: 32.2–46.1), respectively. The NLR was 0.08 (95% CI; 0.02–0.33) and the AUC did not differed from that of the derivation set (0.68 ,95% CI: 0.64–0.72, P = 0.097). Using the Co-LEAD algorithm, 76/250 (30.4%) COVID-19 patients with suspected PE could have been managed without CT pulmonary angiography (CTPA). Conclusion: The Co-LEAD algorithm safely excludes PE, and allows reducing the use of CTPA among COVID-19 patients. Further prospective studies are necessary to validate this strategy.

Fichier principal
Vignette du fichier
main.pdf (1.24 Mo) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-03722805 , version 1 (07-09-2024)

Identifiants

Citer

Benjamin Planquette, Lina Khider, Alice Le Berre, Simon Soudet, Gilles Pernod, et al.. Adjusting D-dimer to lung disease extent to exclude Pulmonary Embolism in COVID-19 patients (Co-LEAD). Thrombosis and Haemostasis, 2022, 122 (11), pp.1888-1898. ⟨10.1055/a-1768-4371⟩. ⟨hal-03722805⟩
701 Consultations
187 Téléchargements

Altmetric

Partager

  • More